Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPID: Quetiapine IR Rapid vs Conventional Titration in Acute Schizophrenia/Schizoaffective Disorder
2006-003519-33Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of quetiapine in schizophrenia and schizoaffective disorder (2 arms), sponsored by AstraZeneca. Primary endpoint: PANSS change at Day 7. Started Dec 2008; status: terminated.
02
Drugs
quetiapine
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on 2006-003519-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003519-33.